在2型糖尿病的临床试验的第三阶段优化样本大小的确定

相关实验视频

Updated: Jun 9, 2025

06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.0K

Alexander C Cambon¹, James Travis¹, Liping Sun¹

¹FDA Center for Drug Evaluation and Research, Office of Translational Science, Office of Biostatistics, Silver Spring, Maryland, USA.

Pharmaceutical statistics

|October 30, 2024

概括

在成人2型糖尿病临床试验中,准确的差异估计可以在不影响有效性的情况下减少样本大小. 这种优化有助于未来的内分泌学研究,并加快试验结果.

科学领域:

临床试验临床试验
内分泌学在内分泌学.
糖尿病研究糖尿病研究

背景情况:

准确的受试者水平差异估计对于确定临床试验中适当的样本大小至关重要.
评估过去的成人2型糖尿病研究将为未来的样本大小要求提供信息.
美国食品和药物管理局 (FDA) 数据库为此类评估提供了有价值的数据.

研究的目的:

在已完成的成人2型糖尿病临床试验中评估差异估计的准确性.
根据历史数据,根据未来研究的样本大小要求提供信息.
调查共变量对剩余标准偏差和样本大小重新估计的影响.

主要方法:

对26项提交给FDA (2013-2017) 的3期随机成年2型糖尿病研究的分析.
从基线到6个月,对糖化血红蛋白 (HbA1c) 的变化对象水平变异的估计.
对9项额外研究的审查,以评估对剩余标准偏差和样本大小的共变量影响.

主要成果:

对于成人2型糖尿病药物试验,减少样本大小是可行的,而不会影响疗效结果的有效性.
来自已完成的研究的差异估计可以指导更有效的样本大小计算.
临床上有意义的共变量可以影响剩余标准偏差和样本大小的重新估计.

结论:

优化样本大小可用于成人2型糖尿病临床试验.
这种优化可以缩短招聘时间,加快研究成果的交付.
这些发现为设计未来内分泌学和糖尿病临床试验提供了宝贵的见解.

关键词:

糖尿病糖尿病患者糖尿病患者样本大小估计的估计.差异差异是指差异的差异.

相关概念视频

01:19

Sample Size Calculation

3.2K

Knowledge of the sample size is the first requirement to conduct random sampling or an experiment. The sample size is the total number of units, observations, or groups (in some cases) used to get the data to estimate a population parameter. As the name suggests, the sample size is that of the sample drawn from the population and differs from the population size.
The sample size for the given experiment or sampling effort is fundamental to any study design. Sample size decides the number of...

3.2K

01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

121

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

121

01:16

Insulin: Dosing Regimen and Adverse Effects

148

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

148

01:15

Diabetes: Management and Pharmacotherapy

237

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

237

01:22

Diabetes Mellitus: Type 2 and Gestational

2.2K

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...